STOCK TITAN

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the company and its collaborators will present preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023 being held April 14-19, 2023, in Orlando, Florida.

Details of the planned presentations are listed below:

Revolution Medicines Oral Presentations:

Title:
 Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor
Presenter: 
 Jim Cregg, Ph.D.
Abstract Number:
 ND07
Session: 
 New Drugs on the Horizon: Part 2
Date/Time: 
 3:45 – 4:00 p.m. Eastern on April 16, 2023


Title: 
 RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models
Presenter:
 Marie Menard, Ph.D.
Abstract Number: 
 3475
Session:
 Immune Checkpoints at Tumor Beds
Date/Time: 
 3:37 – 3:52 p.m. Eastern on April 17, 2023


Revolution Medicines Poster Presentations:

Title:
 RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers
Presenter:
 Lingyan Jiang, Ph.D.
Abstract Number:
 526/26
Session:
 Novel Antitumor Agents 2
Date/Time:
 1:30 – 5:00 p.m. Eastern on April 16, 2023


Title:
 RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
Presenter: 
 Yu C. Yang, Ph.D.
Abstract Number:
 1598/21
Session:
 New Therapeutic Targeted Agents
Date/Time:
 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023


Collaborator Oral Presentation:

Title: 
 Combining KRASG12C(ON) inhibition with SHP2 and immune checkpoint blockade to enhance anti-tumor immunity and overcome development of resistance in lung cancer
Abstract Number:
 5733
Session: 
 New Tricks for Known Targets: Novel Approaches to Inhibit Oncogenic Signaling
Presentation Time: 
 2:37 – 2:52 p.m. Eastern on April 18, 2023


Collaborator Poster Presentations:

Title:
 Bi-steric mTORC1-selective inhibitors activate 4EBP1, suppress MYC, restore anti-tumor immunity, and cooperate with immune checkpoint inhibition to elicit tumor regression
Abstract Number:
 LB015/7
Session:
 Late-Breaking Research: Experimental and Molecular Therapeutics 1
Presentation Time:
 1:30 – 5:00 p.m. Eastern on April 16, 2023


Title: Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma
Abstract Number:  1725/22
Session:  Oncogenes and Tumor Suppressor Genes as Targets for Therapy 2
Date/Time: 9:00 a.m. – 12:30 p.m. Eastern on April 17, 2023


Title: Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1
Abstract Number: 4859/2
Session: Anticancer Approaches Targeting Signal Transduction Pathways
Presentation Time: 1:30 – 5:00 p.m. Eastern on April 18, 2023


Additional information on the AACR Annual Meeting 2023 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2023/

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RASMULTI) and RMC-6291(KRASG12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRASG12D) and RMC-0708 (KRASQ61H), both of which are currently in IND-enabling development, RMC-8839 (KRASG13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

 


Revolution Medicines, Inc.

NASDAQ:RVMD

RVMD Rankings

RVMD Latest News

RVMD Stock Data

7.66B
164.99M
2.39%
98.79%
9.41%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
REDWOOD CITY